Clinical Trial Update: Testing Palbociclib (PD-0332991) as a Potential Targeted Treatment in Cancers With CCND1, 2, 3 Amplification (MATCH-Subprotocol Z1B) [Phase 2]

View source ↗

Summary

Phase 2 MATCH subprotocol study evaluating palbociclib for cancers with CCND1-3 amplification; the trial is active but not recruiting with results previously po…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Malignant Solid Neoplasm

Drugs mentioned

• Palbociclib (palbociclib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2023-08-24